These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6847139)

  • 21. Lisuride in parkinsonism.
    Parkes JD; Schachter M; Marsden CD; Smith B; Wilson A
    Ann Neurol; 1981 Jan; 9(1):48-52. PubMed ID: 7212665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A; Lang AE; Shapiro CM
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
    Bergh T; Nillius SJ; Wide L
    Acta Eur Fertil; 1984; 15(6):421-4. PubMed ID: 6536135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of progressive supranuclear paralysis. Effect of methysergide and bromocriptine on various psychoneurologic and motor functions].
    Giménez-Roldán S; de Andrés C; Salinero E
    Rev Clin Esp; 1979 Apr; 153(1):21-7. PubMed ID: 461893
    [No Abstract]   [Full Text] [Related]  

  • 25. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists.
    Goldstein M; Engel J; Lieberman A; Regev I; Bystritsky A; Mino S
    J Neural Transm Suppl; 1983; 18():257-63. PubMed ID: 6135744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autonomic dysfunction in patients with progressive supranuclear palsy.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Reichmann H; Berg D; Ziemssen T
    Mov Disord; 2008 Oct; 23(14):2083-9. PubMed ID: 18792126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine".
    Lang AE
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):474-82. PubMed ID: 3315148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway.
    Duvoisin RC; Heikkila RE; Manzino L
    Neurology; 1982 Dec; 32(12):1387-91. PubMed ID: 6128698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Antoni S; Ferger D; Reichmann H; Wilhelm H; Berg D; Ziemssen T
    Mov Disord; 2007 Oct; 22(14):2123-6. PubMed ID: 17853484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement.
    Lucetti C; Gambaccini G; Del Dotto P; Ceravolo R; Logi C; Rossi G; Murri L; Bonuccelli U
    Parkinsonism Relat Disord; 2006 Jun; 12(5):279-83. PubMed ID: 16549382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Letter: Efficacy of bromocriptine in 2 cases of levodopa-resistant parkinsonism].
    Kissel P; Andre JM; Jacquier A
    Nouv Presse Med; 1976 Jan; 5(4):210. PubMed ID: 1264671
    [No Abstract]   [Full Text] [Related]  

  • 35. An open label trial of pergolide in Thai patients with Parkinson's disease.
    Poungvarin N; Prayoonwiwat N; Devahasatin V; Viriyavejakul A
    J Med Assoc Thai; 1996 Apr; 79(4):205-9. PubMed ID: 8708504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J; Ulmanová O; Růzicka E
    Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pergolide treatment in parkinsonism.
    Ilson J; Fahn S; Mayeux R; Cote LJ; Snider SR
    Adv Neurol; 1983; 37():85-94. PubMed ID: 6858780
    [No Abstract]   [Full Text] [Related]  

  • 39. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH
    Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pergolide versus bromocriptine.
    Login IS
    Neurology; 1984 Feb; 34(2):258. PubMed ID: 6538025
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.